Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy
Clinical Trial Grant
Awarded By
Novo Nordisk, Inc.
Start Date
April 14, 2026
End Date
January 31, 2029
Awarded By
Novo Nordisk, Inc.
Start Date
April 14, 2026
End Date
January 31, 2029